[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f-vDRti4Kp7Lc6C3B9fTxg2tAkjRLMKAg61OUBPmI_fc":8,"$flXC3KtDn9lQJxJxSdMQTuSh80-2jcGrRIkBg98qS9dw":55,"$fd2SLgQV4Jg4Xnf8wzMFi2ErBCyLe4q7zTb0zVg_EElk":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},66820,863402,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//0Rvlsm1tdkSbq5L99bjhchaojzwJ5kCw.png","华晓萍","浙江大学医学院附属妇产科医院","妇科","主治医师",94,0,"卵巢癌术后靶向治疗用药实用指南","","https://ystcdn.venuertc.com/venue/AI/82dd367d-b00c-4701-82cd-3b7ff4f116c6.jpg","\u003Cdiv id=\"material_title\" class=\"ovarian-guide-title\">\n  \u003Ch1 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">卵巢癌术后靶向治疗用药实用指南\u003C/h1>\n\u003C/div>\n\n\u003Cdiv class=\"ovarian-guide-section\">\n  \u003Cdiv class=\"ovarian-guide-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">什么是卵巢癌术后靶向治疗？🔬\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"ovarian-guide-content\">\n    \u003Cp>\n      靶向治疗，是指通过专门研发的药物，针对肿瘤细胞内的特定分子结构或信号通路起作用，从而在抑制肿瘤生长的同时，尽量减少对正常细胞的影响。卵巢癌术后患者常用的靶向药包括PARP抑制剂，如奥拉帕利片。\u003Cbr>\n      本文将聚焦于靶向药品的核心使用细节，包括服药时间、剂型特点、不良反应、药物相互作用、特殊人群用药、漏服及储存7大要点，帮助你安全用药、规避风险。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"ovarian-guide-section\">\n  \u003Cdiv class=\"ovarian-guide-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">服用时间和方法\u003Cspan aria-label=\"clock\">⏰\u003C/span>\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"ovarian-guide-content\">\n    \u003Cp>\n      奥拉帕利片通常采用每天两次口服的方式。推荐在固定的时间段服用，建议间隔约12小时。服药时可选择餐前、餐后或餐中，但最好保持每日习惯一致，以便稳定吸收和减少胃肠不适。\u003Cbr>\n      正确做法：每次用温水整片吞服，不要压碎、嚼碎或溶解片剂。千万别因为吞咽不畅自行掰开药片，这会影响药物的疗效和安全性。\n    \u003C/p>\n    \u003Cdiv class=\"ovarian-guide-case\">\n      \u003Cstrong>用药案例：\u003C/strong>\u003Cbr>\n      有位患者遵照药师建议，固定在早饭后及晚饭后服用奥拉帕利，显著降低了胃肠不适的概率。\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"ovarian-guide-section\">\n  \u003Cdiv class=\"ovarian-guide-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">剂型特点与服用技巧💊\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"ovarian-guide-content\">\n    \u003Cp>\n      奥拉帕利常见为片剂。每片含有一定剂量的有效成分（规格根据处方或说明书选用）。药片表面完整性，对维持药效非常关键。\u003Cbr>\n      正确做法：必须整片吞服。服用时最好配150-200ml清水，可避免药片卡喉。不要用茶、果汁、奶制品等替代水，因为部分饮品可能影响药物吸收。\n    \u003C/p>\n    \u003Cul class=\"ovarian-guide-list\">\n      \u003Cli>如遇吞咽困难，应寻求医疗人员帮助，不要私自改变给药方式。\u003C/li>\n      \u003Cli>切记不要一次服用超过医生规定的数量。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"ovarian-guide-section\">\n  \u003Cdiv class=\"ovarian-guide-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">药品作用机制简述🔗\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"ovarian-guide-content\">\n    \u003Cp>\n      以奥拉帕利为代表的PARP抑制剂，结构上能精准作用于肿瘤细胞中的PARP酶。当细胞DNA出现损伤时，PARP酶负责修复。这类药物可以“阻断”肿瘤细胞的自我修复功能，使其无法修复DNA损伤，继而导致肿瘤细胞死亡。\u003Cbr>\n      正因其独特机制，奥拉帕利类药物不会像普通化疗药那样大范围杀伤体内细胞，但一样需注意副作用的监测。\n    \u003C/p>\n    \u003Cdiv class=\"ovarian-guide-reference\">\n      参考文献：Ledermann JA, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. \u003Ci>New England Journal of Medicine\u003C/i>, 2012;366(15):1382-1392.\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"ovarian-guide-section\">\n  \u003Cdiv class=\"ovarian-guide-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">用药适应与禁忌事项🚦\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"ovarian-guide-content\">\n    \u003Cp>\n      靶向药物如奥拉帕利主要用于需要维持治疗的患者。但个体差异很大，有些人并不适合使用PARP抑制剂。\n    \u003C/p>\n    \u003Cul class=\"ovarian-guide-list\">\n      \u003Cli>绝对禁忌：对本品及其成分有严重过敏史者，不可使用。\u003C/li>\n      \u003Cli>肝肾严重功能障碍：可能需调整剂量或避免使用。\u003C/li>\n      \u003Cli>孕妇、哺乳期妇女：需在医生指导下权衡利弊。\u003C/li>\n      \u003Cli>年龄、体重与用量可有一定关联，具体须个体化管理。\u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：在开始用药前，必须告诉医生自己的过敏史和用药史。如果在用药期间发现身体出现异样，应当及时联系医生。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"ovarian-guide-section\">\n  \u003Cdiv class=\"ovarian-guide-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">药物相互作用须知🧪\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"ovarian-guide-content\">\n    \u003Cp>\n      奥拉帕利和其他药物同时服用时，可能会产生相互作用，影响疗效或副作用发生。尤其需要注意以下几个方面：\n    \u003C/p>\n    \u003Cul class=\"ovarian-guide-list\">\n      \u003Cli>\n        \u003Cstrong>避免与强CYP3A抑制剂/诱导剂同服：\u003C/strong>如某些抗生素（伊曲康唑）、抗癫痫药，会改变奥拉帕利在体内的浓度。用药期间如需新加药物，务必咨询医生。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>与沃拉帕利等其他PARP类药物不宜联合：\u003C/strong>会增加副作用风险。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>与部分抗生素、抗真菌药、抗癫痫药应留意：\u003C/strong>如需合用，建议严格监测。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"ovarian-guide-reference\">\n      参考文献：European Medicines Agency. Olaparib: Product information. EMA, 2021.\u003Cbr>\n      McNeish IA, Oza AM, Coleman RL, et al. Assessment of the interaction between olaparib and CYP3A4 inhibitors/inducers. \u003Ci>Annals of Oncology\u003C/i>, 2016;27(Suppl 6):vi232-vi240.\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"ovarian-guide-section\">\n  \u003Cdiv class=\"ovarian-guide-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">常见不良反应及处理方法\u003Cspan aria-label=\"warning\">⚠️\u003C/span>\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"ovarian-guide-content\">\n    \u003Cp>\n      PARP抑制剂在实际应用中可能会带来一些不良反应。比较常见的有：\n    \u003C/p>\n    \u003Cul class=\"ovarian-guide-list\">\n      \u003Cli>胃肠道不适（如恶心、呕吐、腹泻）\u003C/li>\n      \u003Cli>轻中度贫血、白细胞减少\u003C/li>\n      \u003Cli>轻度疲乏或乏力\u003C/li>\n      \u003Cli>部分人可能出现口腔溃疡或味觉变化\u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：出现上述轻度不适时，多补充水分、维持均衡饮食。如出现持续不适或明显生理异常（如明显乏力、皮肤黏膜出血等），请及时联系医生，不要自行停药或增加剂量。\n    \u003C/p>\n    \u003Cdiv class=\"ovarian-guide-case\">\n      \u003Cstrong>用药案例：\u003C/strong>\u003Cbr>\n      临床上曾有患者因误服过多奥拉帕利出现明显恶心和低血象，经及时停药和对症处理，情况恢复。\n    \u003C/div>\n    \u003Cdiv class=\"ovarian-guide-reference\">\n      参考文献：Pujade-Lauraine, E., Ledermann, J.A., et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer: phase 3 SOLO2/ENGOT-ov21. \u003Ci>The Lancet Oncology\u003C/i>, 2017;18(9):1274-1284.\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"ovarian-guide-section\">\n  \u003Cdiv class=\"ovarian-guide-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">特殊人群用药管理👩‍⚕️\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"ovarian-guide-content\">\n    \u003Cul class=\"ovarian-guide-list\">\n      \u003Cli>\n        \u003Cstrong>老年人：\u003C/strong>肝肾功能减退常见，医生可能依据检测指标调整剂量。\u003Cbr>\n        \u003Cu>正确做法：\u003C/u>定期随访血常规和肝肾功能，聆听医生建议，不随意增减剂量。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>孕妇和哺乳期女性：\u003C/strong>PARP抑制剂有致畸胎风险，通常不推荐用于孕期，哺乳期需谨慎。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>肝肾功能异常者：\u003C/strong>特别轻度障碍需适度调整剂量，重度损伤者避免使用。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      个体差异较大，需根据医嘱动态治疗和监测。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"ovarian-guide-section\">\n  \u003Cdiv class=\"ovarian-guide-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">漏服和过量处理小贴士📌\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"ovarian-guide-content\">\n    \u003Cp>\n      用药过程中，偶尔漏服或不慎超量是现实中会遇到的问题：\n    \u003C/p>\n    \u003Cul class=\"ovarian-guide-list\">\n      \u003Cli>\u003Cstrong>漏服：\u003C/strong>想起后立即补服，若离下次服药时间不足6小时，此次可跳过，不需加倍剂量。\u003C/li>\n      \u003Cli>\u003Cstrong>忘记多次或长期未服：\u003C/strong>需与医生沟通处理，避免自行大幅补药。\u003C/li>\n      \u003Cli>\u003Cstrong>过量服药：\u003C/strong>有潜在严重风险，可能导致恶心、呕吐、骨髓抑制等。出现明显不适应及时就医。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"ovarian-guide-case\">\n      \u003Cstrong>用药案例：\u003C/strong>\u003Cbr>\n      有患者因家属误会药量而一天服用了三次，感到极度乏力。及时去医院处理后症状缓解，无长期不良影响。\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"ovarian-guide-section\">\n  \u003Cdiv class=\"ovarian-guide-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">储存条件和药品保管🗃️\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"ovarian-guide-content\">\n    \u003Cul class=\"ovarian-guide-list\">\n      \u003Cli>\n        \u003Cstrong>储存：\u003C/strong>建议将奥拉帕利存放于阴凉干燥处，温度不超过25℃。避免高温、潮湿和阳光直射。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>药品包装：\u003C/strong>保留原包装可以阻挡水汽气味，避免误用或污染。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>儿童防护：\u003C/strong>务必放在儿童不可触及的安全位置。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>药品过期：\u003C/strong>超过有效期的药品应规范交由药店或医疗机构回收，别自行丢弃或随意冲进下水道。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确的储存不仅保障药品质量，也确保用药安全性不打折扣。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"ovarian-guide-section\">\n  \u003Cdiv class=\"ovarian-guide-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">总结 &重点回顾📝\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"ovarian-guide-content\">\n    \u003Cp>\n      靶向治疗药物如奥拉帕利，为卵巢癌术后患者带来了新的治疗选择，它作用精准，服用灵活、相对温和，不过也有不少细节要格外注意。\u003Cbr>\n      别忘了：\u003Cbr>\n      \u003Cspan class=\"ovarian-guide-highlight\">① 用药规格和剂量不能自行变动；② 发生副作用或疑虑时及时咨询专业医生。\u003C/span>\u003Cbr>\n      认真阅读说明书，遵医嘱执行，这样才能最大程度发挥药物的效果。同时，请密切关注不良反应和药品相互作用，主动沟通，有疑问不随意停药调整。每一位患者都是独特的，安全用药是保障健康的根本。\u003Cbr>\n      守护身体的每一步，从安心吃药开始。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"ovarian-guide-reference-full\">\n  \u003Ch3 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献\u003C/h3>\n  \u003Cul>\n    \u003Cli>\n      Ledermann JA, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. \u003Ci>New England Journal of Medicine\u003C/i>, 2012;366(15):1382-1392.\n    \u003C/li>\n    \u003Cli>\n      Pujade-Lauraine, E., Ledermann, J.A., et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer: phase 3 SOLO2/ENGOT-ov21. \u003Ci>The Lancet Oncology\u003C/i>, 2017;18(9):1274-1284.\n    \u003C/li>\n    \u003Cli>\n      European Medicines Agency. Olaparib: Product information. EMA, 2021.\n    \u003C/li>\n    \u003Cli>\n      McNeish IA, Oza AM, Coleman RL, et al. Assessment of the interaction between olaparib and CYP3A4 inhibitors/inducers. \u003Ci>Annals of Oncology\u003C/i>, 2016;27(Suppl 6):vi232-vi240.\n    \u003C/li>\n  \u003C/ul>\n\u003C/div>\n\n\u003Cstyle>\n/* 全局风格前缀为 ovarian-guide-，避免样式污染外部页面 */\n.ovarian-guide-title {\n  background: linear-gradient(to right,#ece9f6,#f3f7fa 80%);\n  border-radius:12px;\n  margin:32px auto 24px auto;\n  max-width:900px;\n  padding:24px 24px 12px 24px;\n  text-align:center;\n  box-shadow:0 2px 10px rgba(140,120,180,0.08);\n}\n.ovarian-guide-title h1 {\n  font-size:2.2em;\n  font-weight:700;\n  color:#543b7b;\n  margin:0;\n}\n\n.ovarian-guide-section {\n  margin:16px auto 20px auto;\n  max-width:900px;\n  border-radius:16px;\n  overflow:hidden;\n  border:1.5px solid #ece6fa;\n  box-shadow:0 1px 7px rgba(140,120,180,0.07);\n  background:#fff;\n}\n\n.ovarian-guide-bg {\n  background:linear-gradient(100deg,#f8f4fa 60%,#e6e8f2 100%);\n  padding:18px 28px 10px 28px;\n}\n\n.ovarian-guide-bg h2 {\n  font-size:1.36em;\n  font-weight:600;\n  color:#52567c;\n  margin:0;\n  letter-spacing: 0.03em;\n  display: flex;\n  align-items: center;\n  gap: 9px;\n}\n\n.ovarian-guide-content {\n  padding:18px 34px 16px 34px;\n  font-size:1.11em;\n  line-height:1.85em;\n  color:#34315a;\n  background-color:#ffffff;\n}\n\n.ovarian-guide-content p {\n  margin:0 0 14px 0;\n}\n\n.ovarian-guide-list {\n  margin:7px 0 10px 14px;\n  padding-left:16px;\n}\n.ovarian-guide-list li {\n  margin-bottom:8px;\n  font-size: 1em;\n}\n\n.ovarian-guide-case {\n  background:linear-gradient(94deg,#edf8fa 65%,#f3f6f8 100%);\n  color:#16697a;\n  font-size:1em;\n  border-radius:7px;\n  padding:10px 16px;\n  margin:20px 0 10px 0;\n  border-left: 3.5px solid #64b9db;\n  box-shadow:0 1px 4px rgba(12,110,180,0.03);\n  font-style:italic;\n}\n\n.ovarian-guide-reference {\n  background:#f6f6fb;\n  color:#9992ba;\n  font-size:0.98em;\n  margin:20px 0 6px 0;\n  border-radius:7px;\n  padding:7px 17px;\n  border-left: 2.7px solid #bbaadd;\n}\n\n.ovarian-guide-highlight {\n  background: #ecebfa;\n  padding: 2px 3px 2px 5px;\n  border-radius: 5px;\n  color: #6a4396;\n  font-weight: bold;\n  font-size: 1.01em;\n}\n\n.ovarian-guide-reference-full {\n  margin:30px auto 44px auto;\n  max-width:900px;\n  background:#f5f7fd;\n  border-radius:8px;\n  border: 1px solid #e6e3f2;\n  padding:20px 32px 18px 32px;\n  color:#474466;\n  font-size:1em;\n}\n.ovarian-guide-reference-full h3 {\n  font-size:1.16em;\n  font-weight:600;\n  margin-top:0;\n  color:#6548a2;\n}\n.ovarian-guide-reference-full ul {\n  margin-left:18px;\n  padding-left:8px;\n}\n.ovarian-guide-reference-full li {\n  margin-bottom:7px;\n  line-height:1.65em;\n}\n\u003C/style>\n","\u003Cdiv id=\"material_title\" class=\"ovarian-guide-title\">\n  \u003Ch1 style=\"color: rgb(44, 62, 80); margin: 1",546,"2025-09-19 11:01:08","卵巢癌, 靶向治疗, PARP抑制剂, 药物副作用, 用药指导","本指南详细介绍卵巢癌术后靶向治疗的重要性，包括PARP抑制剂的用法及注意事项，帮助患者安全用药，规避副作用。","2025-10-06 23:30:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]